Roivant Sciences (NASDAQ:ROIV) Stock: Insider Eric Venker Sells 200,000 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker sold 200,000 shares of the business’s stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $36.31, for a total transaction of $7,262,000.00. Following the completion of the sale, the chief executive officer directly owned 999,154 shares in the company, valued at approximately $36,279,281.74. This represents a 16.68% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Eric Venker also recently made the following trade(s):

• On Wednesday, October 28th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $36.59, for a total transaction of $7,318,000.00.
• On Tuesday, October 20th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $35.11, for a total transaction of $7,022,000.00.
• On Wednesday, September 30th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $36.62, for a total transaction of $7,324,000.00.
• On Friday, August 28th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $35.77, for a total transaction of $7,154,000.00.

Roivant Sciences Trading Down 4.2%

Shares of Roivant Sciences stock traded down $1.61 during trading hours on Thursday, reaching $36.62. 10,177,004 shares of the company’s stock were exchanged, compared to its average volume of 6,489,550. The company has a 50 day moving average of $36.67 and a two-hundred day moving average of $31.66. Roivant Sciences Ltd. has a fifty-two week low of $19.79 and a fifty-two week high of $42.50. The stock has a market cap of $26.45 billion, a P/E ratio of -69.09 and a beta of 1.23.

Roivant Sciences (NASDAQ:ROIV) last released its earnings results on Friday, August 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%. The business had revenue of $1.44 million for the quarter, compared to the consensus estimate of $2.06 million. As a group, analysts expect that Roivant Sciences Ltd. will post -2.00 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, September 24th. Wolfe Research cut shares of Roivant Sciences from an “outperform” rating to a “peer perform” rating in a research note on Monday, October 12th. UBS Group set a $55.00 target price on shares of Roivant Sciences in a report on Wednesday, September 9th. Guggenheim upped their price target on shares of Roivant Sciences from $42.00 to $46.00 and gave the stock a “buy” rating in a research report on Wednesday, September 9th. Finally, Jefferies Financial Group increased their price target on shares of Roivant Sciences from $42.00 to $52.00 and gave the company a “buy” rating in a research note on Tuesday, September 8th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $46.55.

Institutional Trading of Roivant Sciences

Several institutional investors and hedge funds have recently bought and sold shares of the business. 71 West Capital Partners grew its position in shares of Roivant Sciences by 573.6% during the 3rd quarter. 71 West Capital Partners now owns 290,735 shares of the company’s stock worth $10,632,000 after purchasing an additional 247,571 shares in the last quarter. AlphaCore Capital LLC acquired a new stake in shares of Roivant Sciences in the third quarter valued at approximately $365,000. Retirement Systems of Alabama raised its position in shares of Roivant Sciences by 19.8% in the third quarter. Retirement Systems of Alabama now owns 558,777 shares of the company’s stock valued at $20,434,000 after buying an additional 92,427 shares in the last quarter. Ethic Inc. boosted its stake in shares of Roivant Sciences by 36.9% in the third quarter. Ethic Inc. now owns 18,226 shares of the company’s stock valued at $667,000 after buying an additional 4,914 shares during the period. Finally, Pictet Asset Management Holding SA boosted its stake in shares of Roivant Sciences by 20.3% in the third quarter. Pictet Asset Management Holding SA now owns 4,173,123 shares of the company’s stock valued at $152,597,000 after buying an additional 704,783 shares during the period. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd. (NASDAQ: ROIV) is a biopharmaceutical company focused on discovering, developing and commercializing medicines. The company organizes its activities through subsidiaries and partner companies, often referred to as “Vants,” which specialize in particular therapeutic areas and stages of drug development.

Roivant’s research and development activities have included immunology, dermatology, women’s health, rare diseases and other specialty-care fields. Its portfolio has included Vtama (tapinarof) cream, a nonsteroidal topical treatment approved in the United States for plaque psoriasis and atopic dermatitis.